Tianxiang Chen1, Quanzhu Yang1, Yongjian Yang1, Yingshu Feng2, Caleb Kesse Firempong3, Xin Zhang1, Haibing He4, Jingwei Jin1 , Hongfei Liu1,3,5
1School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529000; 2Zhenjiang Key Laboratory of Functional Chemistry, Institute of Medicine & Chemical Engineering, Zhenjiang College, Zhenjiang 212028; 3College of Pharmacy, Jiangsu University, Zhenjiang 212013; 4Jiangsu Haizhihong Biomedical Co., Ltd, Nantong 226001; 5Jiangmen Hongxiao Biomedical Co. Ltd, Jiangmen 529000, PR China.For correspondence:- Jingwei Jin Email: wyuchemjjw@126.com Tel:+86- 13646101323
Received: 12 February 2024 Accepted: 2 November 2024 Published: 28 November 2024
Citation: Chen T, Yang Q, Yang Y, Feng Y, Firempong CK, Zhang X, et al. Evaluation of azithromycin–resin suspension designed for taste-masking and sustained-release. Trop J Pharm Res 2024; 23(11):1807-1818 doi: 10.4314/tjpr.v23i11.2
© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To prepare azithromycin (AZI) sustained-release suspension containing AZI-coated microcapsules (AZI-CM) impregnated with AZI-drug resin complex (AZI-DRC), in order to mask the bitter taste of AZI and improve the oral compliance of patients. Methods: The AZI-DRC was prepared using the bath method, with cation exchanger resin Amberlite®IRP64 as a drug carrier, and it was characterized using scanning electron microscopy (SEM), x-ray diffraction (XRD) and Fourier transform infrared (FTIR) spectroscopy. Pretreated AZI-DRC was coated using emulsification-solvent evaporation method to achieve sustained-release effect. The effect of coating on in vitro drug release of the microcapsules was investigated to obtain the optimal AZI-CM through single-factor investigation. The optimized AZI-CM formulation was further dispersed in the optimized suspension matrix to obtain AZI sustained-release suspension. Then, the pharmacokinetics of AZI sustained release from the suspension was studied in rats and compared with commercially available AZI dry suspension. Results: Taste evaluation by volunteers showed that AZI-DRC had a good taste-masking effect on AZI. Results from SEM, XRD and FTIR demonstrated that AZI was present in AZI-DRC solely in amorphous form. Three batches of AZI-CM prepared after optimization produced a significant sustained release effect (p < 0.05). The AZI sustained-release suspension did not change significantly after 10 days and 3 months, indicating good stability (F > 0.9; drug release: f2 > 50; drug leakage < 0.5 %). In vivo results showed that AZI sustained-release suspension had a lower Cmax a higher Tmax and a better bioequivalence than AZI dry suspension available in the market. Conclusion: These findings depict a newly developed AZI sustained-release suspension with improved bioavailability, sustained-release effect, masked bitterness, and good therapeutic effect.
Archives
News Updates